GlassScriptPhysician profile
Douglas P Bennett
NPI 1710903497
$6,711.26
in general payments reported to CMS, 2019-2025
30 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $348 · 2022: $277 · 2023: $1,490 · 2024: $1,344 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,924.59 | 2019-2025 | Biktarvy, Yeztugo, Sunlenca |
| Viiv Healthcare Company | $1,290.47 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Novo Nordisk INC | $511.18 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $409.14 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Tactile Systems Technology INC | $366.10 | 2019-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Theratechnologies INC. | $235.52 | 2019-2024 | Trogarzo, Egrifta Sv, Egrifta |
| Abbvie INC. | $113.93 | 2023-2024 | Mavyret, Synthroid |
| Janssen Biotech, INC. | $105.36 | 2019-2023 | Symtuza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.78 | 2019-2023 | Trulance, Plenvu, Xifaxan |
| Lilly USA, LLC | $72.78 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Bioventus LLC | $66.37 | 2022 | |
| Amarin Pharma, INC. | $55.42 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $49.68 | 2023-2025 | Gvoke Hypopen |
| Emd Serono, INC. | $46.56 | 2019 | |
| Cequr Corporation | $43.80 | 2023-2024 | Cequr Simplicity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.34 | 2019 | |
| Allergan, INC. | $36.82 | 2019 | |
| Becton, Dickinson and Company | $33.86 | 2019 | |
| Mannkind Corporation | $31.30 | 2024 | |
| Medtronic, INC. | $25.60 | 2024 | Minimed 780g |
| Insulet Corporation | $23.40 | 2023 | Omnipod |
| Kerecis Limited | $18.88 | 2019 | |
| Alvogen INC | $18.53 | 2023 | Teriparatide |
| Azurity Pharmaceuticals, INC. | $16.98 | 2023 | Adthyza |
| Corcept Therapeutics | $16.44 | 2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $16.23 | 2019 | |
| Embecta Corp. | $14.89 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Sequel Med Tech, LLC | $14.85 | 2025 | Twiist |
| Shire North American Group INC | $14.24 | 2019 | |
| Amgen INC. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.